Clinical Trial Update: Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck [Phase 1]

View source ↗

Summary

A completed Phase 1 study assessing the safety and tolerability of AG013 in oral mucositis in patients receiving induction chemotherapy for head and neck cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• AG013

Snippet

Sponsor: ActoGeniX N.V. | Conditions: Oral Mucositis | Phase 1 | Status: COMPLETED